Open Access

Options for tracking GFP-Labeled transplanted myoblasts using in vivofluorescence imaging: implications for tracking stem cell fate

  • Zhong Yang1,
  • Yaming Wang2,
  • Yanan Li1,
  • Qiang Liu2,
  • Qing Zeng3 and
  • Xiaoyin Xu3Email author
BMC Biotechnology201414:55

DOI: 10.1186/1472-6750-14-55

Received: 25 January 2014

Accepted: 29 May 2014

Published: 12 June 2014



Green fluorescent protein (GFP) is a useful biomarker, widely used in biomedical research to track stem cells after transplantation and/or to assess therapeutic transgene expression. However, both GFP and therapeutic gene products themselves may be immunogenic to the recipient. The main aim of this study was to use animal models to evaluate potential impact of GFP on the cell engraftment and to optimize tracking strategies prior to transplantation.


By using a fluorescent imaging (FLI) system, we investigated the dynamic cell behavior of GFP-transduced myoblasts in tibialis anterior (TA) muscles of immunocompetent mdx mice and immuno-compromised nude mice over a period of three months. The results suggested an apparent underlying host immunorejection in the mdx mice. Dystrophin immunostaining showed that the engraftment of wild type myoblasts was much more effective than that of the GFP-labeled counterparts in the mdx mice, further confirming an antigen role of GFP in this process. We tracked the GFP-transduced myoblasts in C57BL/6 mice and found GFP to be minimally immunogenic in these animals, as indicated by the GFP signal maintaining a much stronger level than that found in mdx and BALB/c mice at parallel time points. We also compared the in vivo cell behavior differences between myoblasts from virally GFP-transduced and GFP transgenic mice. The latter displayed much better engraftment, as determined both biomaging and histological observations.


Our results not only demonstrated the immunogenicity of GFP in immunocompetent mice, but determined the optimized conditions for GFP-based in vivo stem cells tracking, that can potentially be extrapolated to human biomedical research.


GFP-Labeled Transplanted Myoblasts Fluorescence Imaging Stem Cell


Cell-based therapy in general and transplantation of stem cells in particular, is considered one of the most promising strategies for the treatment of several refractory diseases such as muscular dystrophies, neurodegenerative disorders or cardiac stroke. However, to date, besides the hematopoietic stem cell transplantation, cellular therapies are still far away from being routinely used for clinical purposes [13], and further research is needed to clearly define mechanisms of their pharmaceutical properties and fully understand their potential biological side effects. Therefore, there is a great need for in vivo imaging methods to dynamically track the location, survival and engraftment of transplanted cells [1, 47].

GFP is a useful biomarker, widely used in different kinds of tissues to specifically track transplanted cells’ fate and/or validate the expression of therapeutic transgenes. In the past few years, advances in the field of optical molecular imaging expedited the use of GFP in broader areas of biomedical research [811]. Unfortunately, an unavoidable problem of this technique is the immunogenicity of GFP itself that has been described by several reports [1215]. It is essential to be able to track and assess the engraftment of transplanted stem cells, as their properties and differentiation can be easily affected by multiple factors [1, 8, 16, 17]. Even in a case of fully histocompatible or gene-modified autologous transplantation, many of the therapeutic gene-encoded proteins are immunogenic to the host, requiring administration of immunosuppressants [1820]. As suggested by the previous studies in the field of tumor cell immunological rejection, the ideal transplantation host should be immunocompetent, with minimal immune response to the GFP reporter so as to obtain a better fluorescent signal [21, 22]. The main objective of our study was to evaluate the immunogenic effect of GFP in several animal models, and to determine optimal conditions for GFP-based in vivo stem cells tracking.

Molecular imaging techniques offer a platform that can be used to monitor labeled transplanted cells in living animal not only non-invasively but also continuously and quantitatively. One of the clear advantages in using GFP as a biomarker for optical molecular imaging is that GFP-labeled cells can be directly examined under a fluorescent microscope after tissue harvest. In general, there are two main sources of the GFP-labeled cells: primary cultured cells that are retrovirally GFP-transduced ex vivo, and cells directly isolated from GFP-transgenic animals. So far, both of these sources of GFP-labeled cells are widely used for in vivo cell tracking and optical imaging [2325]. However, for the same type of tissue stem cells, it remains unclear whether some observed discrepancies are a result of the different origin of GFP-labeled cells used, and whether one source should be preferentially chosen in the tracking experiments.

Myoblast transplantation is a cell-based therapy that aims to restore the normal structure of pathogenic muscle and to provide a source of stem cells for muscle repair, and is regarded as a unique way to deliver genes for therapeutic purposes [26, 27]. In the present study, we used the fluorescent imaging in combination with histological observation to show that GFP plays a critical role in the immunorejection response to transplanted GFP-labeled myoblasts. Several animal models were used in this study, including the mdx mouse model for the Duchenne’s muscular dystrophy, that carries the mutation within the dystrophin gene [28], as well as the immunodeficient nude, wild-type BALB/c and C57BL/6 mouse model. We found that the C57BL/6 mouse was a better host candidate than other strains for GFP-labeled myoblasts transplantation because of its minimal immunogenic response to GFP. We demonstrated that GFP-transduced myoblasts possess myogenic differentiation potential and re-enter the satellite niche after transplantation. We also showed that the myoblasts from the GFP transgenic mouse display much more effective engraftment capability compared to ex vivo GFP-transduced ones. We believe that determining optimal conditions for GFP-based in vivo stem cells tracking may potentially contribute to further development of effective cell-based therapies in human subjects.



Imaging experiments used nude, mdx, C57BL/6, and BALB/c WT mice that were obtained from Charles River Laboratories. C57BL/Ka-β-actin-EGFP mice were a gift from A Wagers. The GFP transgenic-mdx hybrid strain was obtained by crossing the male mdx mice with female C57BL/Ka-β-actin-EGFP mice. Genotyping of dystrophin and GFP were performed using PCR (polymerase chain reaction). Adult (6–8 weeks) male mice were used in the study. All animal experimental manipulations were conducted in accordance with a protocol approved by the Institutional Animal Care and Use Committee of Harvard Medical School.

Isolation of primary myoblasts and stable transduction of eGFP gene

The primary myoblasts were isolated from the leg muscles of adult C57BL/10 (an inbred substrain of C57BL/6) or C57BL/Ka-β-actin-EGFP mice using the protocol described by Rando and Blau [29]. After verifying their myogenic identity using immunocytochemistry with an anti-desmin antibody (1:200 dilution, Abcam Biochemicals, Cambridge, MA, USA), myoblasts from C57BL/10 were infected with eGFP-expressing lentiviral vectors. The eGFP-expressing myoblasts were cultured in Ham's F10 medium (Life Technologies, Carlsbad, CA, USA) supplemented with 20% of fetal calf serum (Life Technologies, Carlsbad, CA, USA) and 5 ng/ml basic fibroblast growth factor (Sigma, St Louis, MO, USA). Before cell transplantation, the eGFP expression in the myoblasts was verified using a fluorescence microscope. Cell were trypsinized, and after three washes with phosphate-buffered saline and the determination of cell number, the final cell pellet was suspended in Hanks solution to a final density of 2 × 107–4 × 107 cells/ml.

Myoblasts transplantation

Six to eight week-old male mice were anesthetized by a cocktail of ketamine and xylazine in saline (100 mg/15 mg in 5 ml saline) at a dosage of 100 μl/20 g of body weight. The mouse was placed in a prone position. Non-nude mice leg hair was removed using Nair, a commercially available hair remover (Church & Dwight, Princeton, NJ, USA), and then the leg was wiped with cotton swap dipped in clean water. Using a Hamilton syringe, a total of 5 × 105 eGFP-labeled myoblasts in 20 μl of Hanks were evenly injected at three positions along the axis of tibialis anterior (TA) muscle. After cell injection, the needle was slowly withdrawn in 3 minutes.

Fluorescence imaging station

We used a planar fluorescence imaging station, NightOwl LB981 (Berthold Technologies USA, LLC., Oak Ridge, TN), to acquire the fluorescent imaging (FLI) data and its software toolbox, WinLight 3.2, to process the images. The imaging station features a charge-coupled device (CCD) camera of high sensitivity that can be moved in a vertical direction for optimal focus. The imaging chamber is light-tight to reduce background noise. For the imaging of eGFP, an illumination light source passes through a band-pass filter with a central wavelength of 475 nm to excite the protein, and a band-pass detection filter with a central wavelength of 525 nm selectively captures the emission light of the excited eGFP. The excitation and detection filters have a full-width half magnitude of 40 and 10 nm, respectively. Light photographs of the subjects can be taken by switching off the detection filter.

Imaging procedure and quantification of imaging data

Mice were anesthetized using the protocol described above. Non-nude mice leg hair was removed using Nair as described above. Each mouse was placed in a prone position on a piece of nonfluorescent black paper (Strathmore Series 400). To ensure that TA muscles were imaged in the same position, both legs were positioned 180° apart from each other and 90° relative to the body axis. Both feet were taped to the paper with their dorsal sides up. The CCD camera was set for a field of view of 6.5 cm2 with an estimated specimen height of 0.9 cm. A photographic picture was taken at an exposure time of 10 seconds followed by a fluorescence image at an exposure time of 1,250 ms.

We quantified the measurements with both the normalized photon counts and the area of eGFP signals. The region of interest (ROI) containing eGFP+ signal in the fluorescence images was outlined manually, and then the intensity (photon counts/second/mm2) of the ROI as well as the area of the ROI was recorded. To normalize the fluorescent signal from autofluorescence, we also measured the intensity of an adjacent eGFP region. We then subtracted the photon counts/second/mm2 of ROI by the photon counts/second/mm2 of the eGFParea and calculated the total photon counts generated by eGFP+ cells by timing the normalized intensity within the area of the eGFP+ region.

Muscle harvest, histology and immunohistochemistry staining

Mice were anesthetized with xylazine and ketamine as described above and had their left ventricles perfused with 4% (w/v) paraformaldehyde (PFA, Sigma, St Louis, MO, USA) in phosphate-buffered saline (PBS) (pH 7.4). The TA muscles were then carefully removed. Tissues were post-fixed in 4% PFA over 12 hours, submersed in 30% sucrose overnight, frozen in OCT embedding compound, and sectioned coronally (10 microns) with a cryostat. Cryo-sections were thaw mounted onto gelatin-coated slides and stored at -20°C.

Frozen sections, after being rinsed three times in PBS, were permeabilized and blocked with PBS containing 0.1% (v/v) Triton X-100 and 10% (v/v) goat serum in PBS for 1 hr at room temperature (RT) and then incubated with either rabbit-anti-dystrophin antibody (1:600, Abcam Biochemicals, Cambridge, MA, USA) or mouse-anti-Pax7 antibody (1:50, Hybridoma Bank, Iowa City, IA, USA). The sections were then incubated with the goat-anti-rabbit CyTm5-conjugated or goat-anti-mouse Cy3-conjugated secondary antibody (Jackson Lab) for 1 hr at RT. Slides were counterstained with DAPI dye (1:800, Sigma, St Louis, MO, USA), rinsed and coverslipped with fluorescence mounting medium (Dako, Glostrup Denmark). Stained sections were examined under the Olympus fluorescence microscope (Olympus, Center Valley, PA, USA), and digital images of sections were acquired with a CCD camera.

Statistical analysis

Quantitative data were presented as a means ± standard deviation (SD). A normal distribution of the samples was confirmed and a student’s t-test (assuming equal variances) was performed to determine the statistical significance between two experimental groups. A P value less than 0.05 was considered to be statistically significant.


Transplanted GFP-labeled myoblasts display different engraftment pattern in mice with different immune backgrounds

In the FLI study, we initially investigated the dynamic engraftment of GFP-labeled myoblasts in TA muscles of mdx and immunodeficient nude mice groups for 11 weeks after transplantation. The results revealed that during the first 6 weeks fluorescent signals showed similar changes in the two groups. The TA muscle exhibited its highest fluorescent intensity just after transplantation. Following transplantation, the fluorescent intensity decreased by more than 80% compared to the highest value at 72 h. Then it increased rapidly in the following week, and gradually declined thereafter. After 6 weeks, the intensity remained basically stable in the immunodeficient group, at around 23% of its original value. In contrast, in immunocompetent mdx mice, the fluorescent intensity further weakened to less than 6% of the original value at week 11, suggesting that the immunological rejection response of the host probably played a role in the loss of transplanted myoblasts (Figure 1A-C). This response may be triggered either by GFP or by dystrophin (the latter of which would be regarded as a transgene to the mdx mouse).
Figure 1

Dynamic engraftment of transplanted GFP-labeled myoblasts in tibialis anterior (TA) muscle of mdx and nude mice shown by in vivo fluorescent imaging. The last picture in A and B is the bright-field photo. (A) A representative of dynamic TA muscle imaging in mdx mouse. (B) A representative of dynamic TA muscle imaging in nude mouse. (C) Quantitative data of the GFP fluorescence intensity in mdx and nude mice. PM, GFP-labeled primary myoblast. n = 6.

Reverse transplantation study provides explicit evidence of the immunogenic role of GFP

To assess the effect of allogenic protein GFP on the survival of transplanted myoblasts, we used mdx-GFP hybrid mice. This strain was produced by crossing male mdx with female C57BL/Ka-β-actin-EGFP mice and genotyped before experiment. In this animal model, we transplanted wild type myoblasts passaged in vitro for the same generations as the GFP-modified ones into TA muscles. It excluded the immuno-rejection effect of GFP and was termed reverse transplantation. After one and two months, muscle samples were harvested, and the presence of dystrophin was measured by immunohistochemistry. The dystrophin positive fibers usually displayed a weak green color due to fusion with the GFP positive host fibers in the mdx-GFP hybrid mice. In the mdx mice, the dystrophin positive fibers generally overlapped with the GFP-labeled cells (Figure 2A, B), and a relatively denser infiltration of inflammatory cells could be observed around the dystrophin positive fibers (data not shown). Data showed that at two months after transplantation, mdx-GFP hybrid mice exhibited 2.9 fold higher levels of dystrophin positive fibers than mdx mice (257.6 ± 166.8 versus 88.7 ± 75.2) (Figure 2C).
Figure 2

Dystrophin immunostaining (red) showing the engraftment of transplanted myoblasts in dystrophin-deficient mice. A TA muscle was injected with 5 × 105 cells and harvested 2 months after transplantation. (A) TA muscle of mdx mouse injected with GFP-labeled myoblasts. (B) TA muscle of GFP transgenic-mdx hybrid mouse injected with non-labeled myoblasts. (C) Merged image of A with GFP. (D) Merged image of B with GFP. Scale bar = 20 μm. (E) Levels of dystrophin-positive fibers in TA muscle of mdx mouse injected with GFP-labeled myoblasts (bar A) and of GFP transgenic-mdx hybrid mouse injected with non-labeled myoblasts (bar B). Values are mean ± standard errors of 5 samples. (*P < 0.01; Student’s t-test).

Transplanted GFP-labeled myoblasts engraft much better in the TA muscle of C57BL/6 mice than in other mice strains

To explore the more suitable experimental host for the GFP-labeled cells, we further investigated the survival rate and engraftment efficiency of GFP-labeled myoblasts in C57BL/6 and BALB/c WT mice. Previous tumor cell inoculation study indicated that the immunogenicity of GFP is very low in C57BL/6 mice [21]. When transplanted with the same number of myoblasts (5 × 105) into the TA muscles, the fluorescence intensity of the TA muscles in C57BL/6 mice was significantly higher than that in the BALB/c and mdx mice, and slightly lower than that in the nude mice at one, two and three months after transplantation. Compared with the original value, the fluorescence intensity in all groups significantly decreased one month post-transplantation. However, C57BL/6 mouse model maintained much higher and stable level of fluorescence intensity throughout the experiment, suggesting that the GFP-labeled myoblasts were minimally rejected in these animals. C57BL/6 mouse, therefore has been considered a favorable animal model for research on GFP-labeled cells transplantation (Figure 3).
Figure 3

Fluorescence intensities of TA muscles in of nude, C57BL/6, BALB/c and mdx mice. *P < 0.01, Values are mean ± standard errors of 5 samples.

Myoblasts from the GFP-transgenic mouse exhibit much stronger engraftment capability than that from virally GFP-transduced ex vivo

Next, we evaluated the impact of the GFP-labeled myoblasts derived from different sources on their survival and integration after transplantation in the C57BL/6 mice. Using FLI, we examined the cell behavior of transplanted myoblasts that were obtained either from the GFP transgenic mice or, alternatively, from in vitro transfection with a lentiviral vector containing GFP genes. Fluorescence intensities of the GFP-labeled myoblasts were measured in multi-well culture plates and the intensity of the equal number of cells was standardized for in vivo fluorescence imaging. Cell viability of myoblasts from GFP transgenic mice was significantly higher than cells obtained through the GFP-lentiviral transfection. After transplantation, GFP-labeled myoblasts from transgenic mice presented a stronger fluorescent signal over a wider area, especially at month one and two (Figure 4A, B).These data were further confirmed by analyzing the fluorescence signal of the muscle tissue sections. The green muscle fibers derived from myoblasts of GFP transgenic mice displayed a wider distribution and were more uniform in morphology one month post-transplantation, indicating that myoblasts from GFP-transgenic mice display higher differentiation potential. In contrast, many small and medium-sized cells with green fluorescence could still be observed in the GFP-lentivirus transfection group during the first two months (Figure 4C).
Figure 4

The effect of different origin of GFP-labeled myoblasts on the engraftment in C57BL/6 mice. (A) Representative dynamic TA muscle imaging of GFP-labeled primary myoblasts from transfected in vitro (PM-GFP) and from GFP transgenic mouse (GFP-PM). (B) Fluorescence intensity levels of the PM-GFP and GFP-PM. Data represent means and standard errors of 6 samples; *P < 0.01. (C,D) Histological examination of the TA muscle 1 month after transplantation with PM-GFP (upper panel) and GFP-PM (lower panel). Scale bar = 100 μm.

GFP-transduced myoblasts not only display myogenic differentiation but produce donor-derived satellite cells after transplantation

To evaluate the myogenic differentiation potential of GFP-transduced myoblasts, and especially their capability to generate donor-derived precursor cells of transplanted myoblasts, we examined the engraftment of GFP-labeled cells in TA muscles of immunodeficient nude and C57BL/6 mice by immunofluorescent histochemistry two months after transplantation. Results showed that when transplanted with 5 × 105 myoblasts, hundreds of skeletal muscle fibers marked with GFP could be observed in TA muscles. The engrafted fibers were similar in size to the recipient and displayed green color in various shades based on how they fused with the host fibers. Very few centrally-located nuclei myofibers were observed at that time point. We detected small GFP-positive cells, redistributed in the microenvironment of satellite cells between the basement membrane and myofiber. These cells expressed satellite cells-specific marker, Pax7, indicating that the grafted GFP-labeled myoblasts could not only differentiate to form myofibers, but also reenter in in situ niche to constitute a stored stem cell pool (Figure 5).
Figure 5

Histological evidence of transplanted myoblast-derived satellite cells. The TA muscle was harvested 1 month after transplantation and cryo-sectioned in 10 μm sections. (A) Green channel image shows the eGFP-labeled transplanted cells. (B) Anti-Pax7 immunostaining (red) shows 2 positive cells. (C) DAPI staining show the nuclei of all cells in this area. (D) Merged image of A, B and C. Arrow indicates a transplanted myoblast-derived satellite cell, arrowhead indicates a satellite of the host. Scale bar = 20 μm.


Longitudinal follow-up of the fate of transplanted cells or transgene expression is critical for cell transplantation and gene therapy research. In recent years, in vivo imaging and tracking based on the GFP reporter gene has gradually become one of the most favorable strategies for such studies [1, 11, 30, 31]. Several types of mutant GFP with good stability and enhanced fluorescent brightness have already been commercialized. The enhanced GFP (eGFP) gene in the present study is under the control of the promoter of the conservative actin gene, its fluorescent intensity is kept stable during the culture process and after in vivo transplantation. In a previous study, we monitored the dynamic process of skeletal muscle regeneration by transplanting EGFP-labeled myoblasts in severe combined immune deficiency (SCID) mice, and verified high sensitivity and reliability of this experimental approach [32]. However, determining the potential impact of GFP on the cell engraftment and optimizing the strategy for GFP-based in vivo tracking in disease or immunocompetent animal models, still remains a challenge.

As an exogenous protein, GFP marker was documented to be immunogenic [12, 14, 15]. In the present study, we observed the dynamic processes of transplanted GFP-labeled myoblasts in mice with different immunological backgrounds, as well as reverse transplantation of normal non-labeled myoblasts into mdx-GFP hybrid mice. Our results not only highlighted the immunogenic role of GFP, but also offered a way to assess the effect of transgene (dystrophin) on the survival of transplanted myoblasts.

In optical molecular imaging, consistent expression of the reporter gene is an important prerequisite for the tracking of transplanted living cells. However, the GFP itself was always immunorejected in the immunocompetent host as an exogenous protein. Skelton et al. first reported that GFP was less immunogenic to C57BL/6 mice in which the GFP-transduced EL-4 lymphoma cells could form subcutaneous tumors. However, they hypothesized that this phenomena might be an exception to the rule because the GFP-labeled tumors were rarely noted in other animals or relative species [21, 22]. Our study showed that the fluorescent intensity of GFP-labeled myoblasts after transplantation in C57BL/6 mice was higher than that found in BALB/c and mdx mice, similar to the levels detected in nude mice, confirming that the GFP-transduced myoblasts were only minimally rejected in C57BL/6 mice. To our knowledge, this is first report suggesting that the GFP-transduced stem cells engraft better in C57BL/6 mice than in other species. Furthermore, low rejection rate of GFP-transduced myoblasts in this animal model means that there is no need for additional immunosuppressive agents that may potentially disturb the tissue homeostasis. We suggest therefore, that C57BL/6 mice are a more suitable host animal model for studies that require GFP-labeled stem cells tracking.

In addition to the early massive cell death, host versus graft reaction (HVGR) is a critical determinant of the success of cell transplantation. On condition that a recipient’s genetic background and major histocompatibility are coincident with the donor’s, the immunological response of hosts depends mainly on the structure and the dose of exogenous protein, the route of entry, the type of cells expressing the transgene as well as the viral vector system [16, 33, 34]. In the present study, we show that transplanted myoblasts from GFP-transgenic mice have better engraftment capacity comparing to ex vivo transfection. We used lentivirus vector to obtain ex vivo GFP-transduced myoblasts and obtained highly purified GFP-labeled cells using drug-resistance gene screening and flow cytometry sorting. GFP-labeled myoblasts were also isolated and cultured from transgenic mice in which the GFP gene was stably integrated into the genome at embryonic stage. This method allowed to avoid issues related to the immunogenicity and virulence of the viral vector in the virus-based transfection. It also didn’t have any related toxicity associated with viruses, and thus did not perturbed gene delivery. Consistent with this, studies from Ghazizadeh group indicated that re-transplanting in vitro GFP transfected keratocytes into the host significantly reduced the immune reaction compared with direct injection of the GFP gene, a phenomenon that may be attributed to the lack of the extra antigen brought by in vivo injection of the viral vector [35]. Recently, another study demonstrated that the vector-associated inflammation was reduced through ex vivo gene delivery in lung transplantation [36].

In summary, by combining the use of in vivo FLI, histology and immunohistochemistry, we not only demonstrated the immunogenicity of GFP reporter during cell transplantation, but more importantly, provided optimized conditions for GFP-based tracking using in vivo FLI. We also demonstrated that the immunocompetent C57BL/6 mouse is a better transplant recipient as it shows only minimal immunological rejection of GFP, and GFP transgenic mice appear to be a are better quality cell source than the in vitro transfected ones due to their ability to circumvent the immune response to the vector.


GFP reporter has a distinct immunogenic effect in immunocompetent animal host during cell transplantation. Among several mouse models, C57BL/6 mouse is clearly a better transplant recipient with only minimal immunological rejection of GFP. It appears that GFP transgenic mice are able to evade the immune response to the vector, and therefore, may be considered a better quality cell source, while the use of in vivo FLI provides optimal conditions for GFP-based cell tracking and can potentially be extrapolated in human biomedical research.



This work was supported in part by a grant from the National Natural Science Foundation of China (31171148), and Natural Science Foundation of Chongqing, China ( 2011BB5038). X. Xu’s work was supported by the National Science Foundation (0958345).

Authors’ Affiliations

Department of Clinical Hematology, College of Laboratory Medicine, Southwest Hospital, Third Military Medical University
Department of Anesthesia, Brigham & Women’s Hospital
Department of Radiology, Functional and Molecular Imaging Center, Brigham & Women’s Hospital


  1. Banerjee C: Stem cells therapies in basic science and translational medicine: current status and treatment monitoring strategies. Curr Pharm Biotechnol. 2011, 12 (4): 469-487.View ArticleGoogle Scholar
  2. Janssens S: Stem cells in the treatment of heart disease. Annu Rev Med. 2010, 61: 287-300.View ArticleGoogle Scholar
  3. Skuk D, Tremblay JP: Intramuscular cell transplantation as a potential treatment of myopathies: clinical and preclinical relevant data. Expert Opin Biol Ther. 2011, 11 (3): 359-374.View ArticleGoogle Scholar
  4. Bhakoo K: In vivo stem cell tracking in neurodegenerative therapies. Expert Opin Biol Ther. 2011, 11 (7): 911-920.View ArticleGoogle Scholar
  5. de Almeida PE, van Rappard JR, Wu JC: In vivo bioluminescence for tracking cell fate and function. Am J Physiol Heart Circ Physiol. 2011, 301 (3): H663-H671.View ArticleGoogle Scholar
  6. Sheikh AY, Lin SA, Cao F, Cao Y, van der Bogt KE, Chu P, Chang CP, Contag CH, Robbins RC, Wu JC: Molecular imaging of bone marrow mononuclear cell homing and engraftment in ischemic myocardium. Stem Cells. 2007, 25 (10): 2677-2684.View ArticleGoogle Scholar
  7. Waerzeggers Y, Monfared P, Viel T, Winkeler A, Voges J, Jacobs AH: Methods to monitor gene therapy with molecular imaging. Methods. 2009, 48 (2): 146-160.View ArticleGoogle Scholar
  8. Brazelton TR, Blau HM: Optimizing techniques for tracking transplanted stem cells in vivo. Stem cells. 2005, 23 (9): 1251-1265.View ArticleGoogle Scholar
  9. Chudakov DM, Matz MV, Lukyanov S, Lukyanov KA: Fluorescent proteins and their applications in imaging living cells and tissues. Physiol Rev. 2010, 90 (3): 1103-1163.View ArticleGoogle Scholar
  10. Ma D, Zhang J, Lin HF, Italiano J, Handin RI: The identification and characterization of zebrafish hematopoietic stem cells. Blood. 2011, 118 (2): 289-297.View ArticleGoogle Scholar
  11. Sun N, Lee A, Wu JC: Long term non-invasive imaging of embryonic stem cells using reporter genes. Nat Protocol. 2009, 4 (8): 1192-1201.View ArticleGoogle Scholar
  12. Beagles KE, Peterson L, Zhang X, Morris J, Kiem HP: Cyclosporine inhibits the development of green fluorescent protein (GFP)-specific immune responses after transplantation of GFP-expressing hematopoietic repopulating cells in dogs. Hum Gene Ther. 2005, 16 (6): 725-733.View ArticleGoogle Scholar
  13. Eixarch H, Gomez A, Kadar E, George M, Martinez N, Espejo C, Petriz J, Gimeno R, Barquinero J: Transgene expression levels determine the immunogenicity of transduced hematopoietic grafts in partially myeloablated mice. Mol Ther. 2009, 17 (11): 1904-1909.View ArticleGoogle Scholar
  14. Kung SK, An DS, Bonifacino A, Metzger ME, Ringpis GE, Mao SH, Chen IS, Donahue RE: Induction of transgene-specific immunological tolerance in myeloablated nonhuman primates using lentivirally transduced CD34+ progenitor cells. Mol Ther. 2003, 8 (6): 981-991.View ArticleGoogle Scholar
  15. Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D: Immune response to green fluorescent protein: implications for gene therapy. Gene Ther. 1999, 6 (7): 1305-1312.View ArticleGoogle Scholar
  16. Gu E, Chen WY, Gu J, Burridge P, Wu JC: Molecular imaging of stem cells: tracking survival, biodistribution, tumorigenicity, and immunogenicity. Theranostics. 2012, 2 (4): 335-345.View ArticleGoogle Scholar
  17. Rodriguez-Porcel M, Wu JC, Gambhir SS: StemBook [Internet]. Cambridge (MA): Harvard Stem Cell Institute, 2008-2009.
  18. Bujold M, Caron N, Camiran G, Mukherjee S, Allen PD, Tremblay JP, Wang Y: Autotransplantation in mdx mice of mdx myoblasts genetically corrected by an HSV-1 amplicon vector. Cell Transplant. 2002, 11 (8): 759-767.Google Scholar
  19. Kinoshita I, Vilquin JT, Guerette B, Asselin I, Roy R, Tremblay JP: Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle Nerve. 1994, 17 (12): 1407-1415.View ArticleGoogle Scholar
  20. Swijnenburg RJ, Schrepfer S, Govaert JA, Cao F, Ransohoff K, Sheikh AY, Haddad M, Connolly AJ, Davis MM, Robbins RC, Wu JC: Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc Natl Acad Sci U S A. 2008, 105 (35): 12991-12996.View ArticleGoogle Scholar
  21. Denaro M, Oldmixon B, Patience C, Andersson G, Down J: EGFP-transduced EL-4 cells from tumors in C57BL/6 mice. Gene Ther. 2001, 8 (23): 1814-1815.View ArticleGoogle Scholar
  22. Skelton D, Satake N, Kohn DB: The enhanced green fluorescent protein (eGFP) is minimally immunogenic in C57BL/6 mice. Gene Ther. 2001, 8 (23): 1813-1814.View ArticleGoogle Scholar
  23. Bubnic SJ, Nagy A, Keating A: Donor hematopoietic cells from transgenic mice that express GFP are immunogenic in immunocompetent recipients. Hematology. 2005, 10 (4): 289-295.View ArticleGoogle Scholar
  24. Hakamata Y, Murakami T, Kobayashi E: "Firefly rats" as an organ/cellular source for long-term in vivo bioluminescent imaging. Transplantation. 2006, 81 (8): 1179-1184.View ArticleGoogle Scholar
  25. Persons DA, Allay JA, Riberdy JM, Wersto RP, Donahue RE, Sorrentino BP, Nienhuis AW: Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells. Nat Med. 1998, 4 (10): 1201-1205.View ArticleGoogle Scholar
  26. Partridge TA, Morgan JE, Coulton GR, Hoffman EP, Kunkel LM: Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature. 1989, 337 (6203): 176-179.View ArticleGoogle Scholar
  27. Tedesco FS, Dellavalle A, Diaz-Manera J, Messina G, Cossu G: Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest. 2010, 120 (1): 11-19.View ArticleGoogle Scholar
  28. Grounds MD, Radley HG, Lynch GS, Nagaraju K, De Luca A: Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis. 2008, 31: 1-19.View ArticleGoogle Scholar
  29. Rando TA, Blau HM: Methods for myoblast transplantation. Meth Cell Biol. 1997, 52: 261-272.View ArticleGoogle Scholar
  30. Kircher MF, Gambhir SS, Grimm J: Noninvasive cell-tracking methods. Nat Rev Clin Oncol. 2011, 8 (11): 677-688.View ArticleGoogle Scholar
  31. Tangney M, Francis KP: In vivo optical imaging in gene & cell therapy. Curr Gene Ther. 2012, 12 (1): 2-11.View ArticleGoogle Scholar
  32. Xu X, Yang Z, Liu Q, Wang Y: In vivo fluorescence imaging of muscle cell regeneration by transplanted EGFP-labeled myoblasts. Mol Ther. 2010, 18 (4): 835-842.View ArticleGoogle Scholar
  33. Bessis N, GarciaCozar FJ, Boissier MC: Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 2004, 11 (Suppl 1): S10-S17.View ArticleGoogle Scholar
  34. Zhang Z, Kuscu C, Ghazizadeh S: Transgene-specific host responses in cutaneous gene therapy: the role of cells expressing the transgene. Gene Ther. 2009, 16 (9): 1138-1145.View ArticleGoogle Scholar
  35. Lu Z, Ghazizadeh S: Host immune responses in ex vivo approaches to cutaneous gene therapy targeted to keratinocytes. Exp Dermatol. 2005, 14 (10): 727-735.View ArticleGoogle Scholar
  36. Yeung JC, Wagnetz D, Cypel M, Rubacha M, Koike T, Chun YM, Hu J, Waddell TK, Hwang DM, Liu M, Keshavjee S: Ex vivo adenoviral vector gene delivery results in decreased vector-associated inflammation pre- and post-lung transplantation in the pig. Mol Ther. 2012, 20 (6): 1204-1211.View ArticleGoogle Scholar


© Yang et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.